Get the latest news, insights, and market updates on SRPT (Sarepta Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Does Sarepta’s Move Into Huntington’s siRNA Trials Reframe the Bull Case For Sarepta Therapeutics (SRPT)?
In February 2026, Sarepta Therapeutics announced that New Zealand’s Medsafe approved its clinical trial application for INSIGHTT, a first-in-human Phase 1 study of SRP-1005, an investigational siRNA therapy for Huntington’s Disease, with trial initiation expected in the second quarter of 2026. This move broadens Sarepta’s genetic medicine pipeline beyond muscular disorders into neurodegeneration, targeting a fatal condition with no cure or approved disease-modifying treatments. We’ll now... Feb 14, 2026 - $SRPT
Assessing Sarepta Therapeutics (SRPT) Valuation After Recent Share Price Volatility
Why Sarepta Therapeutics (SRPT) Is Back on Investors’ Radar Sarepta Therapeutics (SRPT) has drawn attention after a period where the share price shows mixed short term performance, including a 2.2% gain over the past day but a 22% decline over the past month. See our latest analysis for Sarepta Therapeutics. At a share price of US$17.79, Sarepta’s short term picture includes a 2.24% 1 day share price return but a 21.97% 30 day share price decline. The 1 year total shareholder return of 83.52%... Feb 14, 2026 - $SRPT
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results
CAMBRIDGE, Mass., February 11, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2025 financial results after the Nasdaq Global Market closes on Wednesday, Feb. 25, 2026. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full-year 2025 financial results. Feb 11, 2026 - $SRPT
Arrowhead Pharmaceuticals Q1 Earnings Call Highlights
Arrowhead Pharmaceuticals (NASDAQ:ARWR) highlighted a series of regulatory, commercial, clinical, and financing milestones in its fiscal 2026 first-quarter earnings call, covering the period ended December 31, 2025. Management emphasized the U.S. approval and launch of its first commercial product, Feb 6, 2026 - $SRPT
Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease
CAMBRIDGE, Mass., February 04, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that Medsafe, the New Zealand Medicines and Medical Devices Safety Authority, has granted approval for its clinical trial application (CTA) for Study SRP-1005-101, also known as INSIGHTT. Sarepta expects to initiate this first-in-human clinical trial of SRP-1005 (formerly ARO-HTT) in the second quarter of 2026. SRP-1005 is an investigational s Feb 4, 2026 - $SRPT
Is Sarepta Therapeutics (SRPT) Pricing Reflect A 82% Share Price Slump And DCF Upside?
If you are wondering whether Sarepta Therapeutics' current share price offers value or just fresh risk, you are not alone. After a very steep 82.1% share price decline over the last year and a 4.6% fall year to date, many investors are reassessing what the recent price level really implies about future expectations. Recent news coverage around Sarepta has focused on regulatory and product pipeline developments alongside changing sentiment in the biotech sector, which helps explain part of... Feb 1, 2026 - $SRPT
Sarepta’s Elevidys Data Underscore Long Term Duchenne Therapy Durability
Sarepta Therapeutics (NasdaqGS:SRPT) reported positive three year functional results from its Phase 3 EMBARK trial of Elevidys in ambulatory Duchenne muscular dystrophy patients. The data show slowed disease progression and sustained motor function benefits over three years, with no new safety concerns disclosed. Elevidys remains the only approved gene therapy for Duchenne muscular dystrophy, making these long term results a key clinical update for the franchise. Sarepta Therapeutics... Feb 1, 2026 - $SRPT
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple